^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | PLX4720 (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Excerpt:
We profiled a panel of 20 BRAF-mutant melanoma and colorectal cancer cell lines for sensitivity to PLX4720...Compared with the melanoma lines, only one colorectal cancer line achieved near-complete suppression of phospho-ERK (COLO205) and was highly sensitive to PLX4720.
DOI:
10.1158/1535-7163.MCT-15-0136-T
